Evolving Molecular Subtyping of Breast Cancer Advances Precision Treatment

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2024 Sep 20

PMID 39302031

Authors

Rui Shan

Lei-Jie Dai

Zhi-Ming Shao

Yi-Zhou Jiang

Affiliations

Soon will be listed here.

References

Li H, Zhu Y, Burnside E, Huang E, Drukker K, Hoadley K . Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ Breast Cancer. 2016; 2. PMC: 5108580. DOI: 10.1038/npjbcancer.2016.12. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Ferrari A, Vincent-Salomon A, Pivot X, Sertier A, Thomas E, Tonon L . A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016; 7:12222. PMC: 4947184. DOI: 10.1038/ncomms12222. View

Couture H, Williams L, Geradts J, Nyante S, Butler E, Marron J . Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. NPJ Breast Cancer. 2018; 4:30. PMC: 6120869. DOI: 10.1038/s41523-018-0079-1. View

Lehmann B, Abramson V, Sanders M, Mayer E, Haddad T, Nanda R . TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2019; 26(9):2111-2123. PMC: 7196503. DOI: 10.1158/1078-0432.CCR-19-2170. View

Sorlie T, Perou C, Tibshirani R, Aas T, Geisler S, Johnsen H . Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98(19):10869-74. PMC: 58566. DOI: 10.1073/pnas.191367098. View

Jiang L, You C, Xiao Y, Wang H, Su G, Xia B . Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer. Cell Rep Med. 2022; 3(7):100694. PMC: 9381418. DOI: 10.1016/j.xcrm.2022.100694. View

Fan L, Wang Z, Ma L, Wu S, Wu J, Yu K . Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024; 25(2):184-197. DOI: 10.1016/S1470-2045(23)00579-X. View

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

10.

Yang F, Xiao Y, Ding J, Jin X, Ma D, Li D . Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2022; 35(1):84-100.e8. DOI: 10.1016/j.cmet.2022.09.021. View

11.

Zuo W, Chen L, Shen Y, Wang Z, Liu G, Yu K . Rational and trial design of FASCINATE-N: a prospective, randomized, precision-based umbrella trial. Ther Adv Med Oncol. 2024; 16:17588359231225032. PMC: 10868472. DOI: 10.1177/17588359231225032. View

12.

Chen L, Jiang Y, Wu S, Wu J, Di G, Liu G . Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial. Clin Cancer Res. 2022; 28(13):2807-2817. PMC: 9365373. DOI: 10.1158/1078-0432.CCR-21-4313. View

13.

Huppert L, Gumusay O, Idossa D, Rugo H . Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023; 73(5):480-515. DOI: 10.3322/caac.21777. View

14.

Nolan E, Lindeman G, Visvader J . Deciphering breast cancer: from biology to the clinic. Cell. 2023; 186(8):1708-1728. DOI: 10.1016/j.cell.2023.01.040. View

15.

Bi W, Hosny A, Schabath M, Giger M, Birkbak N, Mehrtash A . Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019; 69(2):127-157. PMC: 6403009. DOI: 10.3322/caac.21552. View

16.

Ibrahim A, Gamble P, Jaroensri R, Abdelsamea M, Mermel C, Chen P . Artificial intelligence in digital breast pathology: Techniques and applications. Breast. 2020; 49:267-273. PMC: 7375550. DOI: 10.1016/j.breast.2019.12.007. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Zhao S, Ma D, Xiao Y, Li X, Ma J, Zhang H . Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance. Oncologist. 2020; 25(10):e1481-e1491. PMC: 7543239. DOI: 10.1634/theoncologist.2019-0982. View

20.

Gong Y, Ji P, Yang Y, Xie S, Yu T, Xiao Y . Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab. 2020; 33(1):51-64.e9. DOI: 10.1016/j.cmet.2020.10.012. View